Cargando…
Humoral immunity after second dose of BNT162b2 vaccine in Japanese communities: an observational cross-sectional study, Fukushima Vaccination Community Survey
To reveal waning humoral immunity after second dose BNT162b2 vaccinations in a rural Japanese community and determine factors affecting antibody titers. We aimed to report Immunoglobulin G (IgG) antibody against the SARS-CoV-2 spike (S1) protein levels and neutralizing activity in a large scale comm...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9640658/ https://www.ncbi.nlm.nih.gov/pubmed/36344597 http://dx.doi.org/10.1038/s41598-022-21797-x |
_version_ | 1784825906155487232 |
---|---|
author | Kobashi, Yurie Kawamura, Takeshi Shimazu, Yuzo Zhao, Tianchen Sugiyama, Akira Nakayama, Aya Kaneko, Yudai Nishikawa, Yoshitaka Omata, Fumiya Takita, Morihito Yamamoto, Chika Yoshida, Makoto Kosaka, Makoto Murayama, Anju Sugiura, Sota Tanaka, Manato Kawashima, Moe Uchi, Yuna Shindo, Joji Oikawa, Tomoyoshi Shibuya, Kenji Kodama, Tatsuhiko Tsubokura, Masaharu |
author_facet | Kobashi, Yurie Kawamura, Takeshi Shimazu, Yuzo Zhao, Tianchen Sugiyama, Akira Nakayama, Aya Kaneko, Yudai Nishikawa, Yoshitaka Omata, Fumiya Takita, Morihito Yamamoto, Chika Yoshida, Makoto Kosaka, Makoto Murayama, Anju Sugiura, Sota Tanaka, Manato Kawashima, Moe Uchi, Yuna Shindo, Joji Oikawa, Tomoyoshi Shibuya, Kenji Kodama, Tatsuhiko Tsubokura, Masaharu |
author_sort | Kobashi, Yurie |
collection | PubMed |
description | To reveal waning humoral immunity after second dose BNT162b2 vaccinations in a rural Japanese community and determine factors affecting antibody titers. We aimed to report Immunoglobulin G (IgG) antibody against the SARS-CoV-2 spike (S1) protein levels and neutralizing activity in a large scale community based cohort. Methods: Participants in the observational cross-sectional study received a second dose of vaccination with BNT162b2 (Pfizer/BioNTech) and were not previously infected with COVID-19. Questionnaire-collected data on sex, age, adverse vaccine reactions, and medical history was obtained. Results: Data from 2496 participants revealed that older age groups reached a low antibody titer 90–120 days after the second vaccination. Neutralizing activity decreased with age; 35 (13.3%) of those aged ≥ 80 years had neutralizing activity under the cut-off value. Neutralizing activity > 179 days from the second vaccination was 11.6% compared to that at < 60 days from the second vaccination. Significantly lower IgG antibody titers and neutralizing activity were associated with age, male sex, increased time from second vaccination, smoking, steroids, immunosuppression, and comorbidities. Conclusions: Antibody titer decreased substantially over time. Susceptible populations, older people, men, smokers, steroid users, immunosuppression users, and people with three or more comorbidities may require a special protection strategy. |
format | Online Article Text |
id | pubmed-9640658 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-96406582022-11-14 Humoral immunity after second dose of BNT162b2 vaccine in Japanese communities: an observational cross-sectional study, Fukushima Vaccination Community Survey Kobashi, Yurie Kawamura, Takeshi Shimazu, Yuzo Zhao, Tianchen Sugiyama, Akira Nakayama, Aya Kaneko, Yudai Nishikawa, Yoshitaka Omata, Fumiya Takita, Morihito Yamamoto, Chika Yoshida, Makoto Kosaka, Makoto Murayama, Anju Sugiura, Sota Tanaka, Manato Kawashima, Moe Uchi, Yuna Shindo, Joji Oikawa, Tomoyoshi Shibuya, Kenji Kodama, Tatsuhiko Tsubokura, Masaharu Sci Rep Article To reveal waning humoral immunity after second dose BNT162b2 vaccinations in a rural Japanese community and determine factors affecting antibody titers. We aimed to report Immunoglobulin G (IgG) antibody against the SARS-CoV-2 spike (S1) protein levels and neutralizing activity in a large scale community based cohort. Methods: Participants in the observational cross-sectional study received a second dose of vaccination with BNT162b2 (Pfizer/BioNTech) and were not previously infected with COVID-19. Questionnaire-collected data on sex, age, adverse vaccine reactions, and medical history was obtained. Results: Data from 2496 participants revealed that older age groups reached a low antibody titer 90–120 days after the second vaccination. Neutralizing activity decreased with age; 35 (13.3%) of those aged ≥ 80 years had neutralizing activity under the cut-off value. Neutralizing activity > 179 days from the second vaccination was 11.6% compared to that at < 60 days from the second vaccination. Significantly lower IgG antibody titers and neutralizing activity were associated with age, male sex, increased time from second vaccination, smoking, steroids, immunosuppression, and comorbidities. Conclusions: Antibody titer decreased substantially over time. Susceptible populations, older people, men, smokers, steroid users, immunosuppression users, and people with three or more comorbidities may require a special protection strategy. Nature Publishing Group UK 2022-11-07 /pmc/articles/PMC9640658/ /pubmed/36344597 http://dx.doi.org/10.1038/s41598-022-21797-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Kobashi, Yurie Kawamura, Takeshi Shimazu, Yuzo Zhao, Tianchen Sugiyama, Akira Nakayama, Aya Kaneko, Yudai Nishikawa, Yoshitaka Omata, Fumiya Takita, Morihito Yamamoto, Chika Yoshida, Makoto Kosaka, Makoto Murayama, Anju Sugiura, Sota Tanaka, Manato Kawashima, Moe Uchi, Yuna Shindo, Joji Oikawa, Tomoyoshi Shibuya, Kenji Kodama, Tatsuhiko Tsubokura, Masaharu Humoral immunity after second dose of BNT162b2 vaccine in Japanese communities: an observational cross-sectional study, Fukushima Vaccination Community Survey |
title | Humoral immunity after second dose of BNT162b2 vaccine in Japanese communities: an observational cross-sectional study, Fukushima Vaccination Community Survey |
title_full | Humoral immunity after second dose of BNT162b2 vaccine in Japanese communities: an observational cross-sectional study, Fukushima Vaccination Community Survey |
title_fullStr | Humoral immunity after second dose of BNT162b2 vaccine in Japanese communities: an observational cross-sectional study, Fukushima Vaccination Community Survey |
title_full_unstemmed | Humoral immunity after second dose of BNT162b2 vaccine in Japanese communities: an observational cross-sectional study, Fukushima Vaccination Community Survey |
title_short | Humoral immunity after second dose of BNT162b2 vaccine in Japanese communities: an observational cross-sectional study, Fukushima Vaccination Community Survey |
title_sort | humoral immunity after second dose of bnt162b2 vaccine in japanese communities: an observational cross-sectional study, fukushima vaccination community survey |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9640658/ https://www.ncbi.nlm.nih.gov/pubmed/36344597 http://dx.doi.org/10.1038/s41598-022-21797-x |
work_keys_str_mv | AT kobashiyurie humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey AT kawamuratakeshi humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey AT shimazuyuzo humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey AT zhaotianchen humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey AT sugiyamaakira humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey AT nakayamaaya humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey AT kanekoyudai humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey AT nishikawayoshitaka humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey AT omatafumiya humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey AT takitamorihito humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey AT yamamotochika humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey AT yoshidamakoto humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey AT kosakamakoto humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey AT murayamaanju humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey AT sugiurasota humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey AT tanakamanato humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey AT kawashimamoe humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey AT uchiyuna humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey AT shindojoji humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey AT oikawatomoyoshi humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey AT shibuyakenji humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey AT kodamatatsuhiko humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey AT tsubokuramasaharu humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey |